Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis

Hartung, Hans Peter; Steinman, Lawrence; Goodin, Douglas S.; Comi, Giancarlo; Cook, Stuart D.; Filippi, Massimo; O’Connor, Paul; Jeffery, Douglas; Kappos, L; Axtell, Robert C.; Knappertz, Volker; Bogumil, Timon; Schwenke, Susanne; Croze, Ed; Sandbrink, Rupert; Pohl, C

doi:10.1001/jamaneurol.2013.192

Cited by 37 publications

(24 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More research is needed to determine the biomarker potential of synaptic proteins in the CSF. Recent breakthroughs in ultrasensitive immunochemical techniques may help in this regard [187,188].…”

Section: Biomarkers For Synaptic Changesmentioning

confidence: 99%

CSF in Alzheimer's Disease

Zetterberg

Lautner

Skillbäck

et al. 2014

Advances in Clinical Chemistry

View full text Add to dashboard Cite

Section: Biomarkers For Synaptic Changesmentioning

confidence: 99%

CSF in Alzheimer's Disease

Zetterberg

Lautner

Skillbäck

et al. 2014

Advances in Clinical Chemistry

View full text Add to dashboard Cite

“…longstanding disease, which may relate to recent or severe disease 427 activity [104]. It also appears to be loss of activity of regulatory T cells 428 that normally keep inflammation in check [105].…”

mentioning

confidence: 99%

“…IL-17F is one of the signature cytokines of Th17 cells 421 that play a key role in the defense against pathogens and autoimmunity 422 [102] and is a key determinant of aberrant immune responses in MS 423[103]. IL-17 production is increased in relation to disease activity, and 424 decreased by IFN-β therapy[104]. In particular, IL-17 levels are higher 425 in patients recently diagnosed with MS compared to those with 426…”

mentioning

confidence: 99%

Peripheral blood biomarkers in multiple sclerosis

D’Ambrosio

Pontecorvo

Colasanti

et al. 2015

Autoimmunity Reviews

View full text Add to dashboard Cite

Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. The heterogeneity of pathophysiological processes in MS contributes to the highly variable course of the disease and unpredictable response to therapies. The major focus of the research on MS is the identification of biomarkers in biological fluids, such as cerebrospinal fluid or blood, to guide patient management reliably. Because of the difficulties in obtaining spinal fluid samples and the necessity for lumbar puncture to make a diagnosis has reduced, the research of blood-based biomarkers may provide increasingly important tools for clinical practice. However, currently there are no clearly established MS blood-based biomarkers. The availability of reliable biomarkers could radically alter the management of MS at critical phases of the disease spectrum, allowing for intervention strategies that may prevent evolution to long-term neurological disability. This article provides an overview of this research field and focuses on recent advances in blood-based biomarker research.

show abstract

“…Nonetheless, IFN-βefficacy seems to be altered by the profile of encephalitogenic T helper cells; IFN-β alleviates symptoms in conditions with Th1 bias, whereas it promotes pathology in Th17 mediated disease [28,29]. Finally, it was recently suggested that high levels of serum IL-17F above a threshold prior to IFN-β treatment may also be responsible for the non-responsiveness of MS patients [29,30]. Therefore, in order to improve therapeutic approaches, it is imperative to understand how IFN-β exerts its multifaceted actions on different cell types involved in MS.…”

Section: 2ifn-β: As First-line Intervention For Msmentioning

confidence: 99%